The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic adenocarcinoma.
 
Mandana Kamgar
Research Funding - BostonGene; Guardant Health; Rafael Pharmaceuticals (Inst)
 
Husain Yar Khan
No Relationships to Disclose
 
Amro Aboukameel
No Relationships to Disclose
 
Sahar Bannoura
No Relationships to Disclose
 
Brian Y. Chung
No Relationships to Disclose
 
Aniko Szabo
No Relationships to Disclose
 
Yiwei Li
No Relationships to Disclose
 
Mohammed Najeeb Al Hallak
Speakers' Bureau - Ipsen
 
Philip Agop Philip
Honoraria - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb/Medarex; Celgene; Daiichi Sankyo/Astra Zeneca; Guardant Health; Guardant Health; incyte; Ipsen; Merck; Rafael Pharmaceuticals; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Bayer; Bristol-Myers Squibb/Medarex; Celgene; Incyte; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); merus (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals
 
Ben George
Consulting or Advisory Role - Bayer; Boston Scientific; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Ipsen; Roche/Genentech; Taiho Pharmaceutical; TERUMO
Research Funding - Boehringer Ingelheim (Inst); GlycoNex (Inst); Helix BioPharma (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Roche (Inst); Roche/Genentech (Inst); Sirnaomics (Inst); Taiho Pharmaceutical (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst); Trishula Therapeutics (Inst)
 
Kathleen K. Christians
No Relationships to Disclose
 
Douglas B. Evans
No Relationships to Disclose
 
Susan Tsai
No Relationships to Disclose
 
Beth Erickson
Research Funding - Elekta (Inst)
 
Sanjeev Luther
Employment - Cornerstone Pharmaceuticals
Leadership - Cornerstone Pharmaceuticals
Stock and Other Ownership Interests - Cornerstone Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Cornerstone Pharmaceuticals
Travel, Accommodations, Expenses - Cornerstone Pharmaceuticals
 
Asfar S. Azmi
No Relationships to Disclose
 
William A. Hall
Research Funding - Elekta (Inst)
Travel, Accommodations, Expenses - Elekta (Inst)